Hospital de Santa Maria MHM is a public Central Hospital serving the Greater Lisbon area as part of the Northern Lisbon University Hospital Centre, a State-owned enterprise. Santa Maria is the largest hospital in Lisbon and indeed in Portugal.

During the past decade, Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria conducted 142 clinical trials. In the 10-year time frame, 142 clinical trials started and 53 clinical trials were completed, i.e. on average, 37.3% percent of trials that started reached the finish line to date. In the past 5 years, 84 clinical trials started and 41 clinical trials were completed. i.e. 48.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" #1 sponsor was "Boehringer Ingelheim" with 26 trials, followed by "Janssen Research & Development, LLC" with 12 trials sponsored, "Bayer" with 10 trials sponsored, "Amgen" with 9 trials sponsored and "Takeda" with 9 trials sponsored. Other sponsors include 101 different institutions and companies that sponsored additional 75 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Centro de Estudos de Doenças Crónicas" with 2 trials as a collaborator, "Instituto de Medicina Molecular João Lobo Antunes" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "NOVA Medical School" with 2 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" are "Carcinoma, Non-Small-Cell Lung" (6 trials), "Heart Failure" (5 trials), "Amyotrophic Lateral Sclerosis" (4 trials), "Atrial Fibrillation" (4 trials) and "Pulmonary Arterial Hypertension" (4 trials). Many other conditions were trialed in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" in a lesser frequency.

Most popular intervention types in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" are "Drug" (133 trials), "Biological" (14 trials), "Device" (12 trials), "Other" (12 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (50 trials), "Cisplatin" (8 trials), "Gemcitabine" (7 trials), "Docetaxel" (6 trials) and "Pemetrexed" (5 trials). Other intervention names were less common.

The vast majority of trials in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria" are 156 trials for "All" genders, 8 trials for "Male" genders and 7 trials for "Female" genders.

Currently, there are 89 active trials in "Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria". 1 are not yet recruiting, 53 are recruiting, 32 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 71 completed trials in Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, 7 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 97 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 9 trials that are defined as “Not Applicable".